Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of PT-112 combined with gemcitabine in advanced solid tumors
CTR20190817Phase 2Active
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Imifoplatin, gemcitabine in Nonhematologic neoplasms, biliary cancer, sponsored by SciClone Pharmaceuticals (Holdings) Limited. Started Apr 2021; status: active.
02
Drugs
Imifoplatingemcitabine
03
Conditions
Nonhematologic neoplasmsbiliary cancer
Beyond the preview
Go deeper on CTR20190817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190817.